High expression of miR-25 predicts favorable chemotherapy outcome in patients with acute myeloid leukemia
High expression of miR-25 predicts favorable chemotherapy outcome in patients with acute myeloid leukemia
复制标题
miR-25的高表达预示着急性髓系白血病患者良好的化疗结果
DOI：
10.1186/s12935-019-0843-9
复制
发表时间：
2019-05-07
影响因子：
5.8
通讯作者：
Xu, Kailin
中科院分区：
文献类型：
--
作者：
Niu, Mingshan;Feng, Yuan;Xu, Kailin
背景：急性髓系白血病（AML）是一种具有异质性治疗反应的血液系统恶性肿瘤。改善AML患者的风险分层是有必要的。MicroRNAs与AML的发病机制有关。方法将162例新发AML患者根据治疗方案的不同分为两组，研究miR-25的预后价值。结果在化疗组中，miR-25表达上调的患者总体生存期（OS， P= 0.0086）和无事件生存期（EFS， P= 0.019）相对较长。多变量分析显示，miR-25上调是延长OS （HR = 0.556，P= 0.015）和EFS （HR = 0.598，P= 0.03）的独立预测因子。此外，同种异体造血干细胞移植（allogeneic hematopoietic stem cell transplantation, alloo - hsct）避免了与化疗下调miR-25相关的不良预后。miR-25的表达水平模式与AML的分化和增殖一致，其中包括HOXA和HOXB集群成员，以及HOX辅助因子MEIS1。MYH9基因被确定为miR-25的直接靶点。结论miR-25水平与AML预后的相关性独立于其他强大的分子标志物。miR-25的表达可能有助于AML患者在化疗和同种异体hcst之间选择最佳治疗方案。
BackgroundAcute myeloid leukemia (AML) pertains to a hematologic malignancy with heterogeneous therapeutic responses. Improvements in risk stratification in AML patients are warranted. MicroRNAs have been associated with the pathogenesis of AML.MethodsTo examine the prognostic value of miR-25, 162 cases with de novo AML were classified into two groups according to different treatment regimens.ResultsIn the chemotherapy group, cases with upregulated miR-25 expression showed relatively longer overall survival (OS;P= 0.0086) and event-free survival (EFS;P= 0.019). Multivariable analyses revealed that miR-25 upregulation is an independent predictor for extended OS (HR = 0.556,P= 0.015) and EFS (HR = 0.598,P= 0.03). In addition, allogeneic hematopoietic stem cell transplantation (allo-HSCT) circumvented the poor prognosis that was related to miR-25 downregulation with chemotherapy. The expression level pattern of miR-25 coincided with AML differentiation and proliferation, which included HOXA and HOXB cluster members, as well as the HOX cofactor MEIS1. The MYH9 gene was identified as a direct target of miR-25.ConclusionsThe miR-25 levels are correlated with prognosis in AML independently of other powerful molecular markers. The expression of miR-25 may contribute to the selection of the optimal treatment regimen between chemotherapy and allo-HCST for AML patients.